Infinity Pharmaceuticals
Beda Bischof has extensive experience in the field of intellectual property, serving as a Senior Patent Expert and Head of Patent Experts at the Swiss Federal Institute of Intellectual Property since August 1992. In addition to this role, Beda Bischof has worked as an IP Expert at IPI since the same date. Academic qualifications include a Dr. sc.nat in Physics from ETH Zürich, as well as specialized studies in the Chinese intellectual property system and Chinese language and culture from institutions such as SIPO and 台北文化大学. Furthermore, education at China University of Political Science and Law focused on law, including civil law, constitutional law, and intellectual property, emphasizing both legal and linguistic competencies.
This person is not in any offices
Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc., is a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies.